Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | Association of response to first-line chemotherapy with atezolizumab efficacy in mUC

Deniz Tural, MD, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, discusses the association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial cancer (mUC) at ASCO GU 2021. The results from this retrospective analysis of 105 patients suggest that clinical benefit from first-line chemotherapy was an independent prognostic factor of overall survival in patients with urothelial cancer receiving second-line treatment with atezolizumab. This interview took place during the 2021 Genitourinary Cancers Symposium.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.